Isolated Regional Therapy for Advanced Extremity Soft Tissue Sarcomas

Surgical Oncology Clinics of North America

Volumn 21, Issue 2, 2012, Pages 287-299

  Deneve, Jeremiah L ^a   Zager, Jonathan S ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Hyperthermic isolated limb perfusion; Isolated limb infusion; Regional perfusion; Sarcoma; Wieberdink scale

Indexed keywords

CISPLATIN; CORTICOSTEROID; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; MELPHALAN; PAPAVERINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ARTERY THROMBOSIS; BLISTER; BLOOD VESSEL INJURY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CHILL; CLINICAL EFFECTIVENESS; CLOSTRIDIUM INFECTION; COMPARTMENT SYNDROME; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG RESPONSE; EDEMA; ERYTHEMA; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; HYDRATION; HYPERTHERMIC ISOLATED LIMB PERFUSION; HYPOTENSION; INFUSION; ISOLATED LIMB INFUSION; KIDNEY FAILURE; LIMB PERFUSION; LIMB SALVAGE; LOW DRUG DOSE; MUSCLE EDEMA; MYOGLOBINURIA; NAUSEA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; REVIEW; RHABDOMYOLYSIS; SHOCK; SKIN TOXICITY; SOFT TISSUE SARCOMA; SOFT TISSUE TUMOR; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBECTOMY; THROMBOSIS; TISSUE NECROSIS; TREATMENT INDICATION; WOUND INFECTION;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; HUMANS; HYPERTHERMIA, INDUCED; NEOPLASM RECURRENCE, LOCAL; ORGAN SPARING TREATMENTS; PALLIATIVE CARE; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 84857417074     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2011.11.003     Document Type: Review

References (53)

1. Pisters P.W., Leung D.H., Woodruff J., et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996, 14:1679-1689.
2. Williard W.C., Collin C., Casper E.S., et al. The changing role of amputation for soft tissue sarcoma of the extremity in adults. Surg Gynecol Obstet 1992, 175:389-396.
3. Creech O., Krementz E.T., Ryan R.F., et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958, 148:616-632.
4. Collin C.F., Friedrich C., Godbold J., et al. Prognostic factors for local recurrence and survival in patients with localized extremity soft-tissue sarcoma. Semin Surg Oncol 1988, 4:30-37.
5. Collin C., Godbold J., Hajdu S., et al. Localized extremity soft tissue sarcoma: an analysis of factors affecting survival. J Clin Oncol 1987, 5:601-612.
6. Hegazy M.A., Kotb S.Z., Sakr H., et al. Preoperative isolated limb infusion of doxorubicin and external irradiation for limb-threatening soft tissue sarcomas. Ann Surg Oncol 2007, 14:568-576.
7. Lienard D., Ewalenko P., Delmotte J.J., et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992, 10:52-60.
8. Grunhagen D.J., Brunstein F., Graveland W.J., et al. Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg. Ann Surg Oncol 2005, 12:473-479.
9. Eggermont A.M., Schraffordt Koops H., Klausner J.M., et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996, 224:756-764. [discussion: 764-5].
10. Gutman M., Inbar M., Lev-Shlush D., et al. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 1997, 79:1129-1137.
11. Olieman A.F., Pras E., van Ginkel R.J., et al. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 1998, 40:807-814.
12. van Etten B., van Geel A.N., de Wilt J.H., et al. Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol 2003, 10:32-37.
13. Lev-Chelouche D., Abu-Abeid S., Merimsky O., et al. Isolated limb perfusion with high-dose tumor necrosis factor alpha and melphalan for Kaposi sarcoma. Arch Surg 1999, 134:177-180.
14. Grunhagen D.J., de Wilt J.H., Graveland W.J., et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006, 106:1776-1784.
15. Lans T.E., de Wilt J.H., van Geel A.N., et al. Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable Stewart-Treves lymphangiosarcoma. Ann Surg Oncol 2002, 9:1004-1009.
16. Olieman A.F., Lienard D., Eggermont A.M., et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg 1999, 134:303-307.
17. Turaga K.K., Beasley G.M., Kane J.M.I.I.I., et al. Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms. Arch Surg 2011, 146:870-875.
18. Bickels J., Manusama E.R., Gutman M., et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity. Eur J Surg Oncol 1999, 25:509-514.
19. Lejeune F.J., Ghanem G.E. A simple and accurate new method for cytostatics dosimetry in isolation perfusion of the limbs based on exchangeable blood volume determination. Cancer Res 1987, 47:639-643.
20. Wieberdink J., Benckhuysen C., Braat R.P., et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982, 18:905-910.
21. Hoekstra H.J., Schraffordt Koops H., de Vries L.G., et al. Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer 1993, 72:1224-1229.
22. Bonenkamp J.J., Thompson J.F., de Wilt J.H., et al. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol 2004, 30:1107-1112.
23. Briele H.A., Djuric M., Jung D.T., et al. Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Cancer Res 1985, 45:1885-1889.
24. Thompson J.F., Hunt J.A., Shannon K.F., et al. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997, 132:903-907.
25. Lejeune F.J., Pujol N., Lienard D., et al. Limb salvage by neoadjuvant isolated perfusion with TNF alpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol 2000, 26:669-678.
26. Noorda E.M., Vrouenraets B.C., Nieweg O.E., et al. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer 2003, 98:1483-1490.
27. Thompson J.F., Kam P.C., Waugh R.C., et al. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998, 14:238-247.
28. Brady M.S., Brown K., Patel A., et al. Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial. Melanoma Res 2009, 19:106-111.
29. Moncrieff M.D., Kroon H.M., Kam P.C., et al. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Ann Surg Oncol 2008, 15:2749-2756.
30. Brady M.S., Brown K., Patel A., et al. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 2006, 13:1123-1129.
31. Moller M.G., Lewis J.M., Dessureault S., et al. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia 2008, 24:275-289.
32. Sorkin P., Abu-Abid S., Lev D., et al. Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg 1995, 130:1079-1084.
33. Lienard D., Eggermont A.M., Schraffordt Koops H., et al. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 1994, (Suppl 1):21-26.
34. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
35. Renard N., Lienard D., Lespagnard L., et al. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int J Cancer 1994, 57:656-663.
36. Santillan A.A., Delman K.A., Beasley G.M., et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol 2009, 16:2570-2578.
37. Thompson J.F., Kam P.C. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol 2004, 88:1-3.
38. Vrouenraets B.C., Klaase J.M., Nieweg O.E., et al. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol 1998, 14:224-231.
39. Cornett W.R., McCall L.M., Petersen R.P., et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006, 24:4196-4201.
40. Eroglu A., Ozcan H., Eryavuz Y., et al. Deep venous thrombosis of the extremity diagnosed by color Doppler ultrasonography after isolated limb perfusion. Tumori 2001, 87:187-190.
41. Eggimann P., Chiolero R., Chassot P.G., et al. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest 1995, 107:1074-1082.
42. Vrouenraets B.C., Klaase J.M., Kroon B.B., et al. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg 1995, 130:43-47.
43. Eggermont A.M., Schraffordt Koops H., Lienard D., et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996, 14:2653-2665.
44. Bonvalot S., Laplanche A., Lejeune F., et al. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?. Ann Oncol 2005, 16:1061-1068.
45. Rossi C.R., Foletto M., Mocellin S., et al. Hyperthermic isolated perfusion with low-dose TNF alpha and doxorubicin in patients with locally advanced soft tissue limb sarcomas. J Chemother 2004, 16(Suppl 5):58-61.
46. Di Filippo F., Rossi C.R., Vaglini M., et al. Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I study. J Immunother 1999, 22:407-414.
47. Rossi C.R., Vecchiato A., Foletto M., et al. Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 1994, 73:2140-2146.
48. Rouesse J.G., Friedman S., Sevin D.M., et al. Preoperative induction chemotherapy in the treatment of locally advanced soft tissue sarcomas. Cancer 1987, 60:296-300.
49. Suit H.D., Proppe K.H., Mankin H.J., et al. Preoperative radiation therapy for sarcoma of soft tissue. Cancer 1981, 47:2269-2274.
50. Shiu M.H., Hilaris B.S., Harrison L.B., et al. Brachytherapy and function-saving resection of soft tissue sarcoma arising in the limb. Int J Radiat Oncol Biol Phys 1991, 21:1485-1492.
51. Lans T.E., Grunhagen D.J., de Wilt J.G., et al. Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol 2005, 12(5):406-411.
52. Olieman A.F., van Ginkel R.J., Molenaar W.M., et al. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?. Arch Orthop Trauma Surg 1998, 118:70-74.
53. Rossi C.R., Mocellin S., Pilati P., et al. Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas. Ann Surg Oncol 2005, 12:398-405.